1. Mop cover for a cleaning device, comprising two layers, which are connected to each other in such a way that they configure a pouch-type mop cover having an introduction end, where the layers, on their faces facing away from each other, are configured as a wiping surface, the insertion end is closed in segments so as to be undetachable.
2. Mop cover according to claim 1, wherein the layers are configured to be quadrilateral, and in that the layers are connected to each other at three sides, and one side forms the insertion end.
3. Mop cover according to claim 1 wherein the insertion end, starting at its respective corners, a partial section is closed.
4. Mop cover according to claim 3, wherein one partial section is longer than the other partial section.
5. Mop cover according to claim 1, wherein a loop is arranged at one corner.
6. Mop cover according to claim 4, wherein a loop is arranged at the corner that is associated with the shorter partial section.
7. Mop cover according to claim 5, wherein the mop cover presents a color coding.
8. Mop cover according to claim 1, wherein the layers are configured to be trapezoid.
9. Mop cover according to claim 1, wherein at least one of the layers presents a cutout that is open towards the insertion end.
10. Mop cover according to claim 1, wherein the layers are different from each other.
11. Mop cover according to claim 1, wherein the mop cover is elastically expandable.
12. Mop system, comprising a mop cover according to claim 1 and a cleaning device, which comprises a mop plate that is connected by a joint to a handle, where the mop plate presents two main sides, which are attached in such a way that each main side can be pivoted, as desired, in the direction towards the floor to be cleaned.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula (I):
wherein:
R1 is selected from the group consisting of halo, Ay, Het, \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay and \u2014NHR10Het;
each R7 and R8 are the same or different and are independently selected from the group consisting of H, alkyl, alkenyl, cycloalkyl, cycloalkenyl, \u2014OR9, \u2014C(O)R9, \u2014CO2R9, \u2014C(O)NR9R11, \u2014C(S)NR9R11, \u2014C(NH)NR9R11, \u2014SO2R10, \u2014SO2NR9R11, \u2014R10cycloalkyl, \u2014R10OR9, \u2014CH(R10OR9)2, \u2014R10C(O)R9, \u2014R10CO2R9, \u2014R10C(O)NR9R11, \u2014R10C(S)NR9R11, \u2014R10C(NH)NR9R11, \u2014R10SO2R10, \u2014R10SO2NR9R11, \u2014R10SO2NHCOR9, \u2014R10NR9R11, \u2014R10NHCOR9, \u2014R10NHSO2R9 and \u2014R10NHC(NH)NR9R11 and;
each R9 and R11 are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, \u2014R10cycloalkyl, \u2014R10OH, \u2014R10(OR10)w where w is 1-10, and \u2014R10NR10R10;
each R10 is the same or different and is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;
Ay is aryl;
Het is a 5- or 6-membered heterocyclic or heteroaryl group;
n is 0, 1 or 2;
R2 is selected from the group consisting of halo, alkyl, alkenyl, cycloalkyl, cycloalkenyl, Ay, Het, \u2014OR7, \u2014OAy, \u2014OHet, \u2014OR10Het, \u2014S(O)nR9, \u2014S(O)nAy, \u2014S(O)nHet, \u2014S(O)nNR7R8, \u2014NR7R8, \u2014NHHet, \u2014NHR10Ay, \u2014NHR10Het, \u2014R10NR7R8 and \u2014R10NR7Ay;
Y is N;
R3 and R4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ay, Het, \u2014OR7, \u2014OAy, \u2014C(O)R7, C(O)Ay, \u2014CO2R7, \u2014CO2Ay, \u2014SO2NHR9, \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Het \u2014R10OR7, \u2014R10OAy, \u2014R10NR7R8 and \u2014R10NR7Ay;
q is 0, 1, 2, 3, 4 or 5;
each R5 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, \u2014OR7, \u2014OAy, \u2014OHet, \u2014C(O)R9, \u2014C(O)Ay, \u2014C(O)Het, \u2014CO2R9, \u2014C(O)NR7R8, \u2014C(O)NR7Ay, \u2014C(O)NHR10Het, \u2014C(S)NR9R11, \u2014C(NH)NR7R8, \u2014C(NH)NR7Ay, \u2014S(O)nR9, \u2014S(O)2NR7R8, \u2014S(O)2NR7Ay, \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay, \u2014NHR10Het, \u2014R10cycloalkyl, \u2014R10OR9, \u2014R10C(O)R9, \u2014R10CO2R9, \u2014R10C(O)NR9R11, \u2014R10C(S)NR9R11, \u2014R10C(NH)NR9R11, \u2014R10SO2R9, \u2014R10SO2NR9R11, \u2014R10SO2NHCOR9, \u2014R10NR7R8, \u2014R10NR7Ay, \u2014R10NHC(NH)NR9R11, cyano, nitro and azido; or
\u2003two adjacent R5 groups together with the atoms to which they are bonded form a C5-6 cycloalkyl or aryl;
p is 1, 2 or 3; and
each R6 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, \u2014OR7, \u2014OAy, \u2014OHet, \u2014OR10Ay, \u2014OR10Het, \u2014C(O)R9, \u2014C(O)Ay, \u2014C(O)Het, \u2014CO2R9, \u2014C(O)NR7R8, \u2014C(O)NR7Ay, \u2014C(O)NHR10Ay, \u2014C(O)NHR10Het, \u2014C(S)NR9R11, \u2014C(NH)NR7R8, \u2014C(NH)NR7Ay, \u2014S(O)nR9, \u2014S(O)nAy, \u2014S(O)nHet, \u2014S(O)2NR7R8, \u2014S(O)2NR7Ay, \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay, \u2014NHR10Het, \u2014R10cycloalkyl, \u2014R10Ay, \u2014R10Het, \u2014R10OR9, \u2014R10\u2014O\u2014C(O)R9, \u2014R10\u2014O\u2014C(O)Ay, \u2014R10\u2014O\u2014C(O) Het, \u2014R10\u2014O\u2014S(O)nR9, \u2014R10C(O)R9, \u2014R10CO2R9, \u2014R10C(O)NR9R11, \u2014R10C(S)NR9R11, \u2014R10C(NH)NR9R11, \u2014R10SO2R9, \u2014R10SO2NR9R11, \u2014R10SO2NHCOR9, \u2014R10NR7R8, \u2014R10NR7Ay, \u2014R10NHC(NH)NR9R11, cyano, nitro and azido; or
\u2003two adjacent R6 groups together with the atoms to which they are bonded form a C5-6 cycloalkyl or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms; or
\u2003R6 is in the 6 position and R6 and R7 together with the atoms to which they are bonded form a C5-6 cycloalkyl or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms;
or a pharmaceutically acceptable salt or solvate thereof.
2. The compound according to claim 1 wherein R1 is selected from the group consisting of halo, Ay, Het, \u2014NR7R8, \u2014NHHet, \u2014NHR10Ay and \u2014NHR10Het.
3. The compound according to any of claim 1 wherein R1 is selected from the group consisting of Het and \u2014NR7R8.
4. The compound according to any of claim 1 wherein R2 is selected from the group consisting of R2 is selected from the group consisting of Het, \u2014OR7, \u2014OAy, \u2014OHet, \u2014OR10Het, \u2014S(O)nR9, \u2014S(O)nAy, \u2014NR7R8, \u2014NHHet and \u2014NHR10Het.
5. The compound according to claim 1 wherein R2 is selected from the group consisting of Het, \u2014NR7R8 and \u2014NHHet.
6. The compound according to claim 1 wherein R3 and R4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, Ay, \u2014OR7, \u2014CO2R7, \u2014NR7R8, \u2014R10OR7 and \u2014R10NR7R8.
7. The compound according to claim 1 wherein R3 and R4 are each H.
8. The compound according to claim 1 wherein q is 0, 1 or 2.
9. The compound according to claim 1 wherein each R5 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, Ay, Het, \u2014OR7, \u2014OAy, \u2014CO2R9, \u2014C(O)NR7R8, \u2014C(O)NR7Ay, \u2014S(O)2NR7R8, \u2014NR7R8, \u2014NR7Ay, \u2014NHR10Ay, cyano, nitro and azido.
10. The compound according to claim 1, wherein each R5 is the same or different and is independently selected from the group consisting of halo, alkyl, \u2014OR7, \u2014NR7R8 and cyano.
11. The compound according to claim 1 wherein p is 1 or 2.
12. The compound according to claim 1 wherein p is 1.
13. The compound according to claim 1 wherein each R6 is the same or different and is independently selected from the group consisting of halo, alkyl, Ay, Het, \u2014OR7, \u2014OAy, \u2014OHet, \u2014C(O)Het, \u2014CO2R9, \u2014C(O)NR7R8, \u2014C(O)NR7Ay, \u2014C(O)NHR10Het, \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay, \u2014NHR10Het, \u2014R10OR9 and cyano.
14. The compound according to claim 1, wherein each R6 is the same or different and is independently selected from the group consisting of halo, alkyl, \u2014C(O)NR7R8, \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay, and \u2014NHR10Het.
15. A compound selected from the group consisting of:
N-Cyclopentyl-2-(4-fluorophenyl)-3-2-(1-pyrrolidinyl)-4-pyrimidinyl-6-(trifluoromethyl)pyrazolo1,5-apyridin-7-amine;
N-Cyclopentyl-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo1,5-apyridin-7-amine;
Ethyl 7-(cyclopentylamino)-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)pyrazolo1,5-apyridine-6-carboxylate;
7-(Cyclopentylamino)-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)pyrazolo1,5-apyridine-6-carboxylic acid;
N-Cyclopentyl-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)-6-(1-pyrrolidinylcarbonyl)pyrazolo1,5-apyridin-7-amine;
7-(Cyclopentylamino)-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)-N,N -dimethylpyrazolo1,5-apyridine-6-carboxamide;
7-(Cyclopentylamino)-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl) -N-hydroxypyrazolo1,5-apyridine-6-carboxamide;
7-(Cyclopentylamino)-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)-N-2-(4-morpholinyl)ethylpyrazolo1,5-apyridine-6-carboxamide;
7-(Cyclopentylamino)-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)-N-3-(1H-imidazol-1-yl)propylpyrazolo1,5-apyridine-6-carboxamide;
7-(Cyclopentylamino)-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)-N-2-hydroxy-1-(hydroxymethyl)ethylpyrazolo1,5-apyridine-6-carboxamide;
7-(Cyclopentylamino)-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)pyrazolo1,5-apyridin-6-ylmethanol;
N-Cyclopentyl-4-5,7-dichloro-2-(4-fluorophenyl)pyrazolo1,5-apyridin-3-yl-2-pyrimidinamine;
N-{4-5-Chloro-7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo1,5-apyridin-3-yl-2-pyrimidinyl}-N-cyclopentylamine;
N5, N7-Dicyclopentyl-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl) -pyrazolo1,5-apyridine-5,7-diamine;
5-Chloro-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)-N-isopropylpyrazolo1,5-apyridin-7-amine;
3-2-(Cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)-N5,N7-diisopropyl-pyrazolo1,5-apyridine-5,7-diamine;
N-Cyclopentyl-4-5,7-dichloro-2-(4-methoxyphenyl)pyrazolo1,5-apyridin-3-yl-2-pyrimidinamine;
N-{4-5-Chloro-7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo1,5-apyridin-3-yl-2-pyrimidinyl}-N-cyclopentylamine;
5-Chloro-N-cyclopentyl-3-2-(cyclopentylamino)pyrimidin-4-yl-2-(3-methylphenyl)pyrazolo1,5-apyridin-7-amine;
5-Chloro-3-2-(cyclopentylamino)pyrimidin-4-yl-N-cyclopropyl-2-(3-methylphenyl)pyrazolo1,5-apyridin-7-amine;
5-Chloro-N-cyclopentyl-3-2-(cyclopropylamino)pyrimidin-4-yl-2-(3-methylphenyl)pyrazolo1,5-apyridin-7-amine;
5-Chloro-3-2-(cyclopentylamino)-4-pyrimidinyl-N-cyclopropyl-2-(4-fluorophenyl)pyrazolo1,5-apyridin-7-amine;
4-5-Chloro-2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo1,5-apyridin-3-yl-N-cyclopentyl-2-pyrimidinamine;
4 5-Chloro-2-(4-fluorophenyl)-7-(1-piperidinyl)pyrazolo1,5-apyridin-3-yl-N-cyclopentyl-2-pyrimidinamine;
4-5-Chloro-2-(4-fluorophenyl)-7-(4-morpholinyl)pyrazolo1,5-apyridin-3-yl-N-cyclopentyl-2-pyrimidinamine;
N-5-Chloro-3-2-(cyclopentylamino)pyrimidin-4-yl-2-(4-fluorophenyl)pyrazolo1,5-apyridin-7-yl-N\u2032-cyclopentylguanidine hydrochloride;
5-Chloro-N-cyclopropyl-3-2-(cyclopropylamino)pyrimidin-4-yl-2-(4-fluorophenyl)pyrazolo1,5-apyridin-7-amine;
N-cyclopentyl-4-5,7-dichloro-2-(3-chlorophenyl)pyrazolo1,5-apyridin-3-yl-2-pyrimidinamine;
N-{4-5-chloro-2-(3-chlorophenyl)-7-(cyclopentylamino)pyrazolo1,5-apyridin-3-yl-2-pyrimidinyl}-N-cyclopentylamine;
N-{4-5-Chloro-7-(cyclopropylamino)-2-(4-methoxyphenyl)pyrazolo1,5-apyridin-3-yl-2-pyrimidinyl}-N-cyclopentylamine;
4-5-Chloro-3-2-(cyclopentylamino)-4-pyrimidinyl-7-(cyclopropylamino)pyrazolo1,5-apyridin-2-ylphenol;
5-Chloro-3-2-(cyclopentylamino)-4-pyrimidinyl-N-cyclopropyl-2-4-(cyclopropylmethoxy)phenylpyrazolo1,5-apyridin-7-amine;
4-5-Chloro-3-2-(cyclopentylamino)-4-pyrimidinyl-7-(cyclopentylamino)pyrazolo1,5-apyridin-2-ylphenol;
5-Chloro-3-2-(cyclopentylamino)-4-pyrimidinyl-N-cyclopentyl-2-4-(cyclopropylmethoxy)phenylpyrazolo1,5-apyridin-7-amine;
5,7-dichloro-2-(4-methoxyphenyl)-3-2-(methylthio)pyrimidin-4-ylpyrazolo1,5-apyridine;
N-{5-Chloro-2-(4-methoxyphenyl)-3-2-(methylsulfanyl)-4-pyrimidinylpyrazolo1,5-apyridin-7-yl}-N-cyclopentylamine;
N-{5-Chloro-2-(4-methoxyphenyl)-3-2-(methylsulfinyl)-4-pyrimidinylpyrazolo1,5-apyridin-7-yl}-N-cyclopentylamine;
N-{4-5-Chloro-7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo1,5-apyridin-3-yl-2-pyrimidinyl}-N-cyclopropylamine;
4-{5-Chloro-7-(cyclopentylamino)-3-2-(cyclopropylamino)-4-pyrimidinylpyrazolo1,5-apyridin-2-yl}phenol;
N-(4-{5-Chloro-7-(cyclopentylamino)-2-4-(cyclopropylmethoxy)phenylpyrazolo-1,5-apyridin-3-yl}-2-pyrimidinyl)-N -cyclopropylamine;
7-Chloro-N-cyclopentyl-3-2-(cyclopentylamino)pyrimidin-4-yl-2-(4-fluorophenyl)pyrazolo1,5-apyridin-5-amine;
4,6-Dibromo-N-cyclopentyl-3-2-(cyclopentylamino)pyrimidin-4-yl-2-(4-fluorophenyl)pyrazolo1,5-apyridin-7-amine;
4,6-Dibromo-3-5-bromo-2-(cyclopentylamino)pyrimidin-4-yl-N-cyclopentyl-2-(4-fluorophenyl)pyrazolo1,5-apyridin-7-amine;
6-Chloro-N-cyclopentyl-3-2-(cyclopentylamino)pyrimidin-4-yl-2-(4-fluorophenyl)pyrazolo1,5-apyridin-7-amine;
N-Cyclopentyl-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)-5-methoxypyrazolo1,5-apyridin-7-amine; and
N-Cyclopentyl-3-2-(cyclopentylamino)-4-pyrimidinyl-2-(4-fluorophenyl)-5-(2-methoxyethoxy)pyrazolo1,5-apyridin-7-amine,
and pharmaceutically acceptable salts, and solvates thereof.
16. A pharmaceutical composition comprising a compound according to claim 1.
17. The pharmaceutical composition according to claim 16 further comprising a pharmaceutically acceptable carrier or diluent.
18. The pharmaceutical composition according to claim 16 further comprising an antiviral agent selected from the group consisting of aciclovir and valaciclovir.
19. A process for preparing the compound according to claim 1 wherein Y is N, R2 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, Ay, Het, \u2014OR7, \u2014OAy, \u2014OHet, \u2014OR10Het, \u2014S(O)nR9, \u2014S(O)nAy, \u2014S(O)nHet, \u2014S(O)nNR7R8, \u2014NR7R8, \u2014NHHet, \u2014NHR10Ay, \u2014NHR10Het, \u2014R10NR7R8 and \u2014R10NR7Ay; and R3 and R4 are H, said process comprising the steps of:
a) reacting a compound of formula (VIII):
\u2003with a compound of formula (X):
\u2003to prepare a compound of formula (IX):
b) halogenating the compound of formula (IX) to prepare a compound of formula (I-A):
\u2003where Hal is halo; and
c) optionally either:
1) replacing the C-7 halogen of the compound of formula (I-A) with an amine nucleophile selected from the group consisting of \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay and \u2014NHR10Het; or
2) coupling the compound of formula (I-A) with a metal compound selected from the group consisting of Ay-M3 and Het-M3 wherein M3 is \u2014B(OH)2, \u2014B(ORa)2, \u2014B(Ra)2, \u2014Sn(Ra)3, Zn-halide, Zn\u2014Ra or Mg-halide where Ra is alkyl or cycloalkyl and halide is halo, to prepare a compound of formula (I-B):
\u2003wherein R1 is selected from the group consisting of Ay, Het, \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay, and \u2014NHR10Het.
20. A process for preparing the compound according to claim 1 wherein Y is N; R2 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, Ay, Het, \u2014OR7, \u2014OAy, \u2014OHet, \u2014OR10Het, \u2014S(O)nR9, \u2014S(O)nAy, \u2014S(O)nHet, \u2014S(O)nNR7R8, \u2014NR7R8, \u2014NHHet, \u2014NHR10Ay, \u2014NHR10Het, \u2014R10NR7R8 and \u2014R10NR7Ay; R3 is selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Het, \u2014C(O)R7, C(O)Ay, \u2014CO2R7, \u2014CO2Ay, \u2014SO2NHR9, \u2014NR7R8 where neither R7 nor R8 is H, \u2014NR7Ay where R7 is not H, \u2014R10OR7, \u2014R10OAy, \u2014R10NR7R8 and \u2014R10NR7Ay; and R4 is H, said process comprising the steps of:
a) reacting a compound of formula (XVI):
\u2003with a compound of formula (X):
\u2003to prepare a compound of formula (IX):
b) halogenating the compound of formula (IX) to prepare a compound of formula (I-A):
\u2003where Hal is halo; and
c) optionally either:
1) replacing the C-7 halogen of the compound of formula (I-A) with an amine nucleophile selected from the group consisting of \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay and \u2014NHR10Het; or
2) coupling the compound of formula (I-A) with a metal compound selected from the group consisting of Ay-M3 and Het-M3 wherein M3 is \u2014B(OH)2, \u2014B(ORa)2, \u2014B(Ra)2, \u2014Sn(Ra)3, Zn-halide, Zn\u2014Ra or Mg-halide where Ra is alkyl or cycloalkyl and halide is halo; to prepare a compound of formula (I-B):
\u2003wherein R1 is selected from the group consisting of Ay, Het, \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay and \u2014NHR10Het.
21. A process for preparing the compound according to claim 1 wherein Y is N and R2 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, Ay, Het, \u2014OR7, \u2014OAy, \u2014OHet, \u2014OR10Het, \u2014S(O)nR9, \u2014S(O)nAy, \u2014S(O)nHet, \u2014S(O)nNR7R8, \u2014NR7R8, \u2014NHHet, \u2014NHR10Ay, \u2014NHR10Het, \u2014R10NR7R8 and \u2014R10NR7Ay, said process comprising the steps of:
a) reacting a compound of formula (XX):
\u2003with a compound of formula (X):
\u2003to prepare an intermediate compound;
b) oxidizing the intermediate compound to prepare a compound of formula (IX):
c) halogenating the compound of formula (IX) to prepare a compound of formula (I-A):
\u2003where Hal is halo; and
d) optionally either:
1) replacing the C-7 halogen of the compound of formula (I-A) with an amine nucleophile selected from the group consisting of \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay and \u2014NHR10Het; or
2) coupling the compound of formula (I-A) with a metal compound selected from the group consisting of Ay-M3 and Het-M3 wherein M3 is \u2014B(OH)2, \u2014B(ORa)2, \u2014B(Ra)2, \u2014Sn(Ra)3, Zn-halide, Zn\u2014Ra or Mg-halide where Ra is alkyl or cycloalkyl and halide is halo, to prepare a compound of formula (I-B):
\u2003wherein R1 is selected from the group consisting of Ay, Het, \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay and \u2014NHR10Het.
22. A process for preparing the compound according to claim 1, said process comprising the steps of:
a) reacting a compound of formula (XXII):
\u2003wherein X1 is selected from the group consisting of chloro, bromo and iodo;
with a compound of formula (XXIV):
\u2003wherein M2 is selected from the group consisting of \u2014B(OH)2, \u2014B(ORa)2, \u2014B(Ra)2, \u2014Sn(Ra)3, Zn-halide, ZnRa, and Mg-halide where Ra is alkyl or cycloalkyl and halide is halo; to prepare a compound of formula (IX):
b) halogenating the compound of formula (IX) to prepare a compound of formula (I-A):
\u2003where Hal is halo; and
c) optionally either:
1) replacing the C-7 halogen of the compound of formula (I-A) with an amine nucleophile selected from the group consisting of \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay and \u2014NHR10Het; or
2) coupling the compound of formula (I-A) with a metal compound selected from the group consisting of Ay-M3 and Het-M3 wherein M3 is \u2014B(OH)2, \u2014B(ORa)2, \u2014B(Ra)2, \u2014Sn(Ra)3, Zn-halide, Zn\u2014Ra or Mg-halide where Ra is alkyl or cycloalkyl and halide is halo, to prepare a compound of formula (I-B):
\u2003wherein R1 is selected from the group consisting of Ay, Het, \u2014NR7R8, \u2014NR7Ay, \u2014NHHet, \u2014NHR10Ay and \u2014NHR10Het.
23. The process according to claim 19 further comprising the step of converting the compound of formula (I) to a pharmaceutically acceptable salt or solvate thereof.
24. The process according to claim 19 further comprising the step of converting a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof to another compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.